Trevor Hawkins

Summary

Publications

  1. ncbi request reprint Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens
    Trevor Hawkins
    Southwest CARE Center, Santa Fe, NM 87505, USA
    J Acquir Immune Defic Syndr 39:406-11. 2005
  2. ncbi request reprint Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients
    Trevor Hawkins
    Southwest CARE Center, Santa Fe, New Mexico 87505, USA
    HIV Clin Trials 6:187-96. 2005
  3. ncbi request reprint Appearance-related side effects of HIV-1 treatment
    Trevor Hawkins
    Southwest CARE Center, University of New Mexico, Santa Fe, 87505, USA
    AIDS Patient Care STDS 20:6-18. 2006
  4. doi request reprint Understanding and managing the adverse effects of antiretroviral therapy
    Trevor Hawkins
    Department of Family Practice, University of New Mexico, United States
    Antiviral Res 85:201-9. 2010
  5. ncbi request reprint Impact of once- and twice-daily dosing regimens on adherence and overall safety
    Trevor Hawkins
    University of New Mexico, Sante Fe, New Mexico, USA
    AIDS Read 14:320-2, 324, 329-31, 334-6. 2004
  6. pmc Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients
    Trevor Hawkins
    Southwest CARE Center, Santa Fe, New Mexico, USA
    Antimicrob Agents Chemother 55:1549-55. 2011
  7. ncbi request reprint Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    J Acquir Immune Defic Syndr 43:1-5. 2006
  8. ncbi request reprint Advances in HIV therapeutics: news from the 4th International AIDS Society Conference
    Brian A Boyle
    AIDS Read 17:484-90. 2007
  9. ncbi request reprint HIV drug resistance and you. The limitations of drug resistance testing. Many factors influence the results
    Trevor Hawkins
    Posit Aware . 2006

Detail Information

Publications9

  1. ncbi request reprint Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens
    Trevor Hawkins
    Southwest CARE Center, Santa Fe, NM 87505, USA
    J Acquir Immune Defic Syndr 39:406-11. 2005
    ..To evaluate the potential for a pharmacologic mechanism to explain suboptimal virologic responses observed in a triple-nucleoside only regimen containing tenofovir disoproxil fumarate (TDF), abacavir (ABC), and lamivudine (3TC)...
  2. ncbi request reprint Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients
    Trevor Hawkins
    Southwest CARE Center, Santa Fe, New Mexico 87505, USA
    HIV Clin Trials 6:187-96. 2005
    ..To compare the extent of neuropsychiatric disturbances in two similar groups of HIV-infected patients treated for >4 weeks with either efavirenz (EFV) or protease inhibitors (PIs) as part of their antiretroviral therapy (ART)...
  3. ncbi request reprint Appearance-related side effects of HIV-1 treatment
    Trevor Hawkins
    Southwest CARE Center, University of New Mexico, Santa Fe, 87505, USA
    AIDS Patient Care STDS 20:6-18. 2006
    ..This paper reviews the appearance-related side effects associated with classes of antiretroviral drugs as well as individual agents, including the newer antiretrovirals...
  4. doi request reprint Understanding and managing the adverse effects of antiretroviral therapy
    Trevor Hawkins
    Department of Family Practice, University of New Mexico, United States
    Antiviral Res 85:201-9. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol. 85, issue 1, 2010...
  5. ncbi request reprint Impact of once- and twice-daily dosing regimens on adherence and overall safety
    Trevor Hawkins
    University of New Mexico, Sante Fe, New Mexico, USA
    AIDS Read 14:320-2, 324, 329-31, 334-6. 2004
    ..Clinical data to guide individual treatment decisions are limited, and therapy--whether a once-daily, twice-daily, or other dosing schedule--should be selected based on individual patient needs...
  6. pmc Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients
    Trevor Hawkins
    Southwest CARE Center, Santa Fe, New Mexico, USA
    Antimicrob Agents Chemother 55:1549-55. 2011
    ..The association between longer-term ddI therapy and reduced intracellular nucleotide concentrations and this observation's implication for the efficacy and toxicity of ddI-containing regimens deserve further study...
  7. ncbi request reprint Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
    Edwin DeJesus
    Orlando Immunology Center, Orlando, FL, USA
    J Acquir Immune Defic Syndr 43:1-5. 2006
    ..GS-9137 is a potent low-nanomolar strand transfer inhibitor of HIV-1 integrase...
  8. ncbi request reprint Advances in HIV therapeutics: news from the 4th International AIDS Society Conference
    Brian A Boyle
    AIDS Read 17:484-90. 2007
  9. ncbi request reprint HIV drug resistance and you. The limitations of drug resistance testing. Many factors influence the results
    Trevor Hawkins
    Posit Aware . 2006